Break a bone, tear a ligament, or go under the knife, and your muscle starts shrinking almost immediately. So can creatine, the most-studied supplement in sports nutrition, stop it? A new systematic review in Experimental Physiology gives a split answer. During the immobilisation itself, the evidence is mixed and unconvincing. During rehab, there are hints that creatine may help you rebuild faster. Those hints come from very few studies, though.
This is human research, but a small and narrow slice of it. Here is what the review found and what it can't tell you.
What the Researchers Actually Did
A team led by Pratt, with Candow, Rawson, Forbes and Prokopidis, searched PubMed, Scopus, Web of Science and the Cochrane Library from inception to March 2026. They followed PRISMA guidelines for systematic reviews.
They found six randomised, placebo-controlled trials with 118 participants in total. The mean ages ran from 15 to 24 years. The disuse model in every case was one to two weeks of limb immobilisation. They examined muscle size, lean mass, and performance (strength, power, endurance) during disuse and, where available, during recovery.
The review is a systematic review of the evidence, not a new trial. The trials were small and varied, which limits how far the pooled picture can be pushed.
Round One: Does Creatine Stop the Shrinkage?
Not clearly. The results contradict each other.
Muscle size (quadriceps cross-sectional area, measured by CT or NMR imaging): Two studies found creatine did essentially nothing. Reductions were -5.6% with creatine versus -5.5% with placebo in one, and -11.0% versus -9.4% in the other.
Lean mass (measured by BIA or DXA): Two studies reported a benefit.
- Lower-limb lean mass fell 5.6% with creatine versus 8.9% with placebo.
- Upper-limb lean mass was preserved (+0.9%) with creatine versus -3.7% with placebo.
That looks like a win until you consider how the measurements were taken.
The Water Problem
The authors caution that the contrasting findings may reflect limitations of BIA and DXA, including hydration effects, rather than real preservation of muscle tissue. Creatine pulls water into cells. Both methods can read extra fluid as lean mass, so a "lean mass" advantage may partly be water. The imaging methods (CT and NMR) look at actual muscle size, and they showed no real difference.
The review does not claim creatine is useless here. It says the lean-mass signal can't be trusted as proof that muscle was saved.
Strength and Power During Disuse
Performance results were inconsistent. Creatine showed favourable effects in upper-limb models but not lower-limb models. Why the split? The review doesn't settle it. With so few small trials, any explanation would be speculation. The authors conclude that current evidence does not unanimously support creatine as a countermeasure against disuse-induced atrophy, lean mass loss, or performance decline.
Round Two: The Comeback
This is where the review gets more interesting. Four of the six studies included a recovery phase, and three used resistance-based rehabilitation. Two of them reported bigger gains with creatine:
- Quadriceps CSA: +21.3% vs. +14.3% with placebo
- Lower-limb lean mass: +5.6% vs. +3.8%
- Power: +52.2% vs. +35.2%
- Strength: +28.7% vs. +22.8%
Those are meaningful gaps on paper. But only two studies reported them, the participants were young, and the lean-mass number carries the same hydration caveat. Treat it as a promising lead, not a proven rehab protocol.
Limitations You Should Know
- Small evidence base: six trials, 118 people.
- Young participants only: ages 15-24. Older adults and clinical patients, who are most at risk of disuse atrophy and incomplete recovery, were not represented. The authors explicitly call for research in these groups.
- Short disuse: one to two weeks of immobilisation, shorter than many real-world casts or post-surgical periods.
- Measurement issues: BIA and DXA can be confounded by water.
- Only two studies showed the rehab advantage.
- Conflicts of interest: several authors disclosed industry-sponsored creatine research, creatine donations, advisory roles with creatine manufacturers, and expert-witness work in creatine cases. That doesn't invalidate the review, and its conclusion is notably cautious, but readers should know.
Practical Takeaways
Dose: The review's abstract doesn't recommend a dose. The standard evidence-based approach for creatine monohydrate is 3-5 g per day. Some trials used a loading phase first, which is optional. Take it daily, since timing relative to training matters far less than consistency.
Timing: Starting around the time of immobilisation and continuing through rehab is the pattern the trials examined. Don't expect it to prevent the shrinkage you see on the first day out of the cast.
Who it might suit: Healthy, otherwise-fit people facing a short period of limb immobilisation who plan to do progressive resistance rehab. Creatine is already well studied in exercising populations, so adding it is a reasonable, low-cost experiment.
Who should skip it or ask first: Anyone with kidney disease or other medical conditions, anyone on medications that affect kidney function, and anyone pregnant or breastfeeding should check with a doctor first. Older adults and clinical patients should also be cautious about assuming these results apply to them, since they weren't studied.
The non-negotiable: Creatine supports training, it doesn't replace it. The rehab benefits appeared in studies using resistance-based rehabilitation. Follow your physio's plan and load the muscle progressively as soon as it's cleared.
The Bottom Line
Creatine is not a force field for your muscle while it's in a cast. The size data show little protection, and the lean-mass wins may partly be water. But the rehab phase offers a more intriguing signal: faster regrowth, power, and strength in two studies. It's a plausible edge for young, healthy people doing real rehab work, but it needs bigger, longer trials, especially in older and clinical groups, before anyone should call it proven.
